Fig. 2From: Vitamin C sensitizes BRAFV600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032Vitamin C sensitized BRAFMT thyroid cancer cells to PLX4032. a Cells were pre-treated with Vitamin C (VC) or vehicle for 6 h, followed by treating with different concentrations of PLX4032 (upper panels) or VC (lower panels) for 48 h, MTT assay was employed to evaluate cell viability. MTT assay (b) and colony formation assay (c) were used to evaluate the proliferation inhibitory effect of combining therapy. Data were presented as mean ± SD. ns, not significant; */^/#, P < 0.05; **/^^/##, P < 0.01; ***/^^^/###, P < 0.001. */ns: compared with control group; ^: compared with VC group; #: compared with PLX4032 groupBack to article page